In a complete response letter (CRL), the FDA said it was not asking for any additional clinical data for Ultomiris as a treatment for NMOSD, but is looking for modifications to the risk evaluation ...

Although your particular field of study or type of assessment may not be represented, viewing a rubric that is designed for a similar assessment may give you ideas for the kinds of criteria, ...